IRADIMED CORPORATION Reports Record Third Quarter 2025 Financial Results

IRADIMED CORPORATION, a leader in developing innovative MRI-compatible medical devices, has released its financial results for the third quarter of 2025. The company reported record revenue and earnings, alongside a regular quarterly cash dividend and raised full-year guidance.

Financial Highlights

For the third quarter of 2025, IRADIMED CORPORATION reported a record revenue of $21.2 million, marking a 16% increase compared to the same period in 2024. The company also achieved a record GAAP diluted EPS of $0.43 and non-GAAP diluted EPS of $0.47, reflecting increases of 8% and 9%, respectively, from the previous year. Net income for the quarter was $5.6 million, up from $5.0 million in the third quarter of 2024.

Business and Operational Highlights

The company experienced a strong gross margin of 78% despite some transitional inefficiencies due to moving into a new facility in Orlando. The new facility is now fully operational, enabling the company to meet accelerating demand. The backlog for both pump and monitor systems is at an all-time high. Additionally, IRADIMED is set to begin limited commercial shipments of its next-generation 3870 MRI-compatible IV infusion pump in December, with full U.S. commercialization expected in the first quarter of 2026.

Strategic Initiatives and Corporate Developments

IRADIMED CORPORATION declared a regular quarterly cash dividend of $0.17 per share, payable on November 25, 2025. The company also raised its full-year 2025 guidance, now expecting revenue between $82.5 million and $83.5 million, and GAAP diluted EPS between $1.68 and $1.72.

Management's Perspective

Roger Susi, President and CEO of IRADIMED, expressed pride in the company's seventeenth consecutive quarter of record revenue. He highlighted the dedication of employees during the transition to the new facility and emphasized the company's commitment to operational excellence, innovation, and consistent shareholder returns.

Future Outlook

For the fourth quarter of 2025, IRADIMED expects revenue between $21.4 million and $22.4 million, GAAP diluted EPS between $0.43 and $0.47, and non-GAAP diluted EPS between $0.47 and $0.51. The company also provided updated full-year guidance, projecting revenue between $82.5 million and $83.5 million, GAAP diluted EPS between $1.68 and $1.72, and non-GAAP diluted EPS between $1.84 and $1.88.

Original SEC Filing: IRADIMED CORP [ IRMD ] - 8-K - Nov. 03, 2025